Home > Insider Trading > Astrazeneca Plc

Astrazeneca Plc (AZN)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

First
<< Previous
221 - 230
Next >>

FDA Sends Complete Response Letter To AstraZeneca PLC (ADR) (AZN) Following Rejection Of Hyperkalemia Drug

AstraZeneca PLC (ADR) (NYSE:AZN) has acknowledged the receipt of the Complete Response Letter (CRL) from the U.S. Food and Drug Administration for ZS-9, a drug designed to treat hyperkalemia.

Keep Reading →

March 21st, 2017 - News Stock Analysis

AstraZeneca PLC (ADR) (AZN) In Respiratory Drug Deal With Circassia Pharmaceuticals

In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued at $50 million in the respiratory biopharmaceutical firm.

Keep Reading →

March 20th, 2017 - News Stock Analysis

AstraZeneca PLC (ADR) (AZN)'s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO)

Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression.

Keep Reading →

March 16th, 2017 - News Stock Analysis

Here's What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology Inc (CLVS)

It’s been a big week for PARP inhibitors. AstraZeneca PLC (ADR) (NYSE:AZN) just put out data from a phase 3 investigation of its lead PARP asset Lynparza, and the data came out as impressive.

Keep Reading →

March 15th, 2017 - News Stock Analysis

7 Most Popular Diet Pills That Work Fast Without Exercise

Are you interested in knowing the 7 Most Popular Diet Pills That Work Fast Without Exercise? I mean what better way to lose weight than to simply pop some pills and let the fat melt away, right? Of course...

Keep Reading →

March 15th, 2017 - Lists News

AstraZeneca PLC (ADR) (AZN) Rejected Drugs To Be Reconsidered

AstraZeneca plc (ADR) (NYSE:AZN) is reconsidering some of its rejected drugs, as they could possess potential in curing a disease they were not initially meant to treat.

Keep Reading →

March 14th, 2017 - News Stock Analysis

China MediTech And AstraZeneca PLC (ADR) (AZN) To Present Savolitinib Phase II Results At The Genitourinary Cancers Symposium 2017

Hutchison China MediTech Limited and AstraZeneca plc (ADR) (NYSE:AZN) are to present data from their phase II clinical trials of Savolitinib, at the upcoming 2017 Genitourinary Cancers Symposium.

Keep Reading →

February 15th, 2017 - News Stock Analysis

Clovis Oncology Inc (CLVS)'s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO)

According to Debjit Chattopadhyay, a Janney analyst, trials from AstraZeneca and Tesaro are likely to change the role of PARP inhibitors from being second to front-line treatments.

Keep Reading →

January 31st, 2017 - News Stock Analysis

AstraZeneca PLC (ADR) (AZN) Wins A Six Months Paediatric Exclusivity Approval Of Its Symbicort

The US Food and Drug Administration (FDA) has confirmed that Symbicort (budesonide/formoterol) Inhalation Aerosol is worth being granted paediatric exclusivity.

Keep Reading →

January 30th, 2017 - News Stock Analysis